+352.5%
SNPS vs MRNA
+554.4%
-201.9%
-42.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.1% | +5.4% | -5.3% | -0.2% |
| 7D | +0.9% | -1.1% | +2.0% | +0.9% |
| 30D | -3.6% | +126.1% | -129.7% | -12.0% |
| 3M | -12.9% | +190.0% | -202.9% | -22.9% |
| 6M | -8.2% | +157.2% | -165.4% | -18.0% |
| YTD | -15.4% | +388.2% | -403.6% | -29.5% |
| 1Y | -9.3% | +467.0% | -476.3% | -25.9% |
| 3Y | -14.0% | +36.1% | -50.0% | -22.5% |
| 5Y | +19.5% | -68.0% | +87.5% | +13.6% |
| All | +352.5% | +554.4% | -201.9% | +277.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling